Anika Therapeutics vs Owlet
Anika Therapeutics reported revenue of $113 million in fiscal 2025, about the same as Owlet's $106 million in fiscal 2025. Anika Therapeutics' revenue fell 5.9% in its latest year, and Owlet's grew 35.4%. Anika Therapeutics had an operating margin of -9.8%, against -7.8% at Owlet. Free cash flow was $4 million at Anika Therapeutics and −$11 million at Owlet.
Side by side
| Anika Therapeutics | Owlet | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $113M | $106M |
| Revenue growth | −5.9% | 35.4% |
| Revenue growth a year, last 5 years | −2.9% | 7.0% |
| Gross margin | 56.6% | 50.6% |
| Operating margin | −9.8% | −7.8% |
| Net margin | −9.6% | −37.5% |
| Free cash flow | $4M | −$11M |
| Free cash flow margin | 3.9% | −10.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $10M | $0M |
| Change in diluted share count | −2.6% | 65.2% |
| Last close | $13.28 | $3.23 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $264,308, sold $0 | sold $295,978 |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Anika TherapeuticsOwlet
Operating margin
Percent of revenue
Anika TherapeuticsOwlet
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Anika TherapeuticsOwlet
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Anika Therapeutics and Owlet pages.